Excess in Vitro Secretion of the Free α-Subunit of the Glycoprotein Hormones by Pituitary Cells from Chronically Uremic Rats*

Endocrinology ◽  
1982 ◽  
Vol 110 (6) ◽  
pp. 1964-1971 ◽  
Author(s):  
MARC R. BLACKMAN ◽  
GARY R. BRIEFEL ◽  
PANAYIOTIS D. TSITOURAS ◽  
MITCHELL S. HARMAN
1990 ◽  
Vol 127 (1) ◽  
pp. 149-159 ◽  
Author(s):  
S. Muttukrishna ◽  
P. G. Knight

ABSTRACT Primary cultures of ovine pituitary cells (from adult ewes) were used to investigate the actions of steroid-free bovine follicular fluid (bFF) and highly-purified Mr 32 000 bovine inhibin on basal and gonadotrophin-releasing hormone (GnRH)-induced release of FSH and LH. Residual cellular contents of each hormone were also determined allowing total gonadotrophin content/well to be calculated. As in rats, both crude and highly purified inhibin preparations promoted a dose (P < 0·001)- and time (P < 0·001)-dependent suppression of basal and GnRH-induced release of FSH as well as an inhibition of FSH synthesis, reflected by a fall in total FSH content/well. However, while neither inhibin preparation affected basal release of LH or total LH content/well, GnRH-induced LH release was significantly (P< 0·001) increased by the presence of either bFF (+ 75%) or highly-purified inhibin (+ 64%) in a dose- and time-dependent manner. This unexpected action of bFF on GnRH-induced LH release was abolished in the presence of 5 μl specific anti-inhibin serum, confirming that the response was indeed mediated by inhibin. Furthermore, neither oestradiol-17β (1 pmol/l–10 nmol/l) nor monomeric α-subunit of bovine inhibin (2·5–40 ng/ml) significantly affected basal or GnRH-induced release of LH. These in-vitro findings for the ewe lend support to a number of recent in-vivo observations and indicate that, in addition to its well-documented suppressive effect on the synthesis and secretion of FSH, inhibin may actually facilitate LH release in this species, in marked contrast to its action in the rat. Journal of Endocrinology (1990) 127, 149–159


1995 ◽  
Vol 144 (1) ◽  
pp. 173-178 ◽  
Author(s):  
S L Atkin ◽  
R V Jeffreys ◽  
P M Foy ◽  
L Hipkin ◽  
J Radcliffe ◽  
...  

Abstract The effects of human recombinant basic fibroblastic growth factor (bFGF) on the secretion, viability, proliferation, attachment and morphology of ten dispersed human clinically non-functional (NF) adenomas were examined in vitro. Four clinically NF adenomas secreting FSH and/or LH in vitro were unaffected by 10 nm bFGF over a 4-h period. Over 4 days 10 nm bFGF stimulated LH secretion (66% and 72%, P<0·01) from two out of seven clinically NF adenomas secreting LH, whilst FSH (three tumours) and α-subunit secretion (three tumours) were unaffected. One adenoma co-secreting LH and α-subunit and one secreting LH alone were studied over 21 days; LH secretion fell progressively, but the decline was significantly less (P<0·05) with bFGF (10 nm) treatment after 14 and 21 days in both adenomas, whilst the fall in α-subunit secretion was unaffected by bFGF treatment. A 24-h GnRH test performed at the start and end of the 21-day period in one of these tumours showed an increase in both basal and stimulated LH secretion in the bFGF-treated group over control (124%, P<0·001). There was no effect of bFGF (10 nm) on viability, S-phase proliferation, attachment or morphology of adenoma cells over a 4-day period. These results suggest that bFGF has a role in tumorous LH secretion from these adenomas, but is not mitogenic (at least over 4 days) and is without effect on other parameters of in vitro differentiated function. Journal of Endocrinology (1995) 144, 173–178


1997 ◽  
Vol 45 (7) ◽  
pp. 985-990 ◽  
Author(s):  
Shigeyasu Tanaka ◽  
Shingo Kurabuchi ◽  
Hiroshi Mochida ◽  
Hiroaki Hayashi ◽  
Katsumi Wakabayashi

To obtain an antibody specific for the α-subunit of rat pituitary glycoprotein hormones, we synthesized a peptide corresponding to the sequence 37–53 (ST-7: Phe-Ser-Arg-Ala-Tyr-Pro-Thr-Pro-Ala-Arg-Ser-Lys-Lys-Thr-Met-Leu-Val) of the rat α-subunit. The polyclonal antiserum against this peptide was generated in rabbits. This region is hydrophilic and highly conserved among several mammalian species. Noncompetitive binding tests showed that the ST-7 antiserum had specific affinity for the rat free α-subunit, but not for rat intact LH, FSH, and TSH. The ST-7 antiserum immunostained two types of cells in the rat anterior pituitary, i.e., gonadotrophs and thyrotrophs. This was also the case in mouse, cattle, sheep, and pig, which have an identical sequence of ST-7 in their α-subunit. The pituitary cells of horse (Arg substituted for Lys as residue 48 of the rat α-subunit), human, and eel (Leu for Ala at residue 45), chicken (Met for Ala at residue 45), and bullfrog (Tyr for Phe at residue 37 and Met for Ala at residue 45) were not stained with the ST-7 antiserum. This study indicated that the ST-7 antiserum is sequence-specific for the α-subunit and is therefore useful for immunohistochemical studies on the secretory pathway of the free α-subunit.


1993 ◽  
Vol 129 (6) ◽  
pp. 565-572 ◽  
Author(s):  
George Kontogeorgos ◽  
Sylvia L Asa ◽  
Kalman Kovacs ◽  
Harley S Smyth ◽  
William Singer

Somatotroph adenomas of the pituitary secrete growth hormone in excess and are associated with acromegaly. Morphologically, they can be separated into two entities, densely and sparsely granulated variants. It has been shown that a number of somatotroph adenomas produce α-subunit of glycoprotein hormones; however, it is not clear whether α-subunit production correlates with tumor cell morphology. We studied 32 surgically removed pituitary somatotroph adenomas in tissue culture to determine structure-function correlations of growth hormone and α-subunit production. All tumors were classified on the basis of detailed histological, immunocytochemical and electron-microscopic studies. Fifteen tumors were densely granulated and 1 7 were sparsely granulated. In addition to growth hormone, all 15 densely granulated tumors released α-subunit in vitro, whereas of the 1 7 sparsely granulated tumors only 4 released α-subunit moreover, the mean baseline levels of α-subunit were significantly higher in densely granulated adenomas than in sparsely granulated adenomas. Parallel response of release of both hormones was found during stimulation with growth hormone-releasing hormone or thyrotropin-releasing hormone and during suppression with somatostatin or bromocriptine in densely granulated tumors. α-subunit response to stimulation or suppression could not be determined with significance in sparsely granulated tumors because of low basal levels. The results indicate that α-subunit production and release is characteristic of densely granulated somatotroph adenomas and that α-subunit is coregulated with growth hormone by adenohypophysiotropic substances; in contrast, α-subunit production by sparsely granulated somatotroph adenomas is rare and, when present, much lower in quantity. Our studies confirm that densely and sparsely granulated somatotroph adenomas represent separate entities.


1997 ◽  
Vol 82 (3) ◽  
pp. 889-896 ◽  
Author(s):  
D. M. Robertson ◽  
N. Cahir ◽  
J. K. Findlay ◽  
H. G. Burger ◽  
N. Groome

Abstract In a previous study (see Ref. 7), the molecular weight distribution of inhibin activity in fractionated human follicular fluid (hFF) and human male and female plasma/serum was determined by in vitro bioassay using ovine pituitary cells in culture and various specific inhibin A and inhibin α-subunit-directed immunoassays. It was shown, however, that the ovine in vitro bioassay detected inhibin B poorly. These findings are extended in the present study by the determination of the molecular weight profile of in vitro bioactivity using rat pituitary cells, which detects both inhibin A and B, a specific inhibin B enzyme-linked immunosorbent assay (ELISA), an RIA detecting the αN region of the α-subunit, anα -subunit ELISA (Pro-αC) directed to the inhibin forms containing the Pro sequence, and an αC subunit immunofluorometric assay that detects all inhibin forms. The profile in hFF of inhibin in vitro bioactivity, using rat pituitary cells in culture, significantly (P &lt; 0.001) correlated with in vitro bioactivity using ovine pituitary cells (r= 0.85), inhibin A immunoactivity (r = 0.70), inhibin B immunoactivity (r = 0.89), and the combination of inhibin A+B immunoactivities (r = 0.93), with peaks of activity identified at 66K, 55K, 36K and 33K, consistent with presumed known mol wt forms of inhibin. Inhibin B profiles in fractionated serum from women stimulated with gonadotropins and male plasma consisted of two forms (66K and 36K), whereas inhibin A in female serum included, in addition, the 55K form. These findings indicated that higher molecular weight forms of inhibin B are present in biological samples, and their distribution differs from that of inhibin A, suggesting a differential processing of the precursor forms in the circulation. Pro-αC immunoactivity was identified in serum samples with prominent peaks at 36K and 29K (known Pro-αC subunit forms) and not with any high mol wt dimeric forms of inhibin. If this observation applies to a wider range of serum samples, the Pro-αC ELISA may provide an appropriate and specific assay for the measurement of free α-subunit. To compare immunoactivity levels between assays, the inhibins A, B, and Pro-αC standards were calibrated in terms of their αC subunit content, as determined by anα C subunit immunoassay, with the inhibin B standard containing 60% of the αC subunit content compared with either the inhibin A or Pro-αC standard. After adjustments of the various standards for this difference in αC subunit content, a comparison was undertaken of the combined levels of inhibins A, B, and Pro-αC immunoactivity across the hFF and serum chromatograms and compared with levels determined by the α-subunit-directed immunoassays. A high correlation (r = 0.59–0.96) was observed, indicating that the α-subunit immunoactivity in serum consists largely of a composite of presumed known molecular weight forms of inhibins A, B, and Pro-αC. It is concluded that: 1) inhibin in vitro bioactivity in hFF is largely attributed to the presence of 33–36K and 50–66K forms of inhibins A and B; and 2) inhibin α-subunit immunoactivity in hFF and serum is a composite of presumed known forms of inhibin A, inhibin B, and the α-subunit.


1998 ◽  
Vol 83 (5) ◽  
pp. 1598-1603
Author(s):  
J. Ham ◽  
J. Webster ◽  
J. A. Bond ◽  
B. Jasani ◽  
M. D. Lewis ◽  
...  

A major problem in the study of human pituitary cells is their lack of proliferative capacity in vitro. To address this issue, we have infected normal human, postmortem pituitary cells in monolayer culture with a temperature-sensitive (tsA58) mutant of SV40 large T antigen. Several epithelial-like colonies were isolated; and one, designated CHP2, has been studied in detail to identify its functional characteristics. CHP2 cells have undergone more than 150 culture passages and retain an epithelial morphology. They exhibit tight temperature-dependent growth, in the presence and absence of serum, with cell division at 33 C and growth inhibition at 39 C. CHP2 cells, at both temperatures, showed diffuse immunostaining for humanα -subunit and focal staining for TSHβ. Gene expression was confirmed by RT-PCR and sequencing. TRH and GnRH receptors were not detectable, and their absence was confirmed by their lack of effects on intracellular calcium and inositol phospholipids. Cytogenetic analysis showed that the cells had a modal peak in the diploid range and a smaller peak in the tetraploid range. There was also a consistent loss of chromosome 22 and a normal chromosome 2 homologue, the latter being replaced by one of two chromosome 2 markers, M2A or M2B. In conclusion, we have immortalized human pituitary cells using SV40 tsT, from which we have cloned a cell line expressing α-subunit and TSHβ.


2005 ◽  
Vol 19 (9) ◽  
pp. 2412-2423 ◽  
Author(s):  
Mark S. Roberson ◽  
Stuart P. Bliss ◽  
Jianjun Xie ◽  
Amy M. Navratil ◽  
Todd A. Farmerie ◽  
...  

Abstract Our previous studies demonstrate that GnRH-induced ERK activation required influx of extracellular Ca2+ in αT3-1 and rat pituitary cells. In the present studies, we examined the hypothesis that calmodulin (Cam) plays a fundamental role in mediating the effects of Ca2+ on ERK activation. Cam inhibition using W7 was sufficient to block GnRH-induced reporter gene activity for the c-Fos, murine glycoprotein hormone α-subunit, and MAPK phosphatase (MKP)-2 promoters, all shown to require ERK activation. Inhibition of Cam (using a dominant negative) was sufficient to block GnRH-induced ERK but not c-Jun N-terminal kinase activity activation. The Cam-dependent protein kinase (CamK) II inhibitor KN62 did not recapitulate these findings. GnRH-induced phosphorylation of MAPK/ERK kinase 1 and c-Raf kinase was blocked by Cam inhibition, whereas activity of phospholipase C was unaffected, suggesting that Ca2+/Cam modulation of the ERK cascade potentially at the level of c-Raf kinase. Enrichment of Cam-interacting proteins using a Cam agarose column revealed that c-Raf kinase forms a complex with Cam. Reconstitution studies reveal that recombinant c-Raf kinase can associate directly with Cam in a Ca2+-dependent manner and this interaction is reduced in vitro by addition of W7. Cam was localized in lipid rafts consistent with the formation of a Ca2+-sensitive signaling platform including the GnRH receptor and c-Raf kinase. These data support the conclusion that Cam may have a critical role as a Ca2+ sensor in specifically linking Ca2+ flux with ERK activation within the GnRH signaling pathway.


Endocrinology ◽  
2007 ◽  
Vol 148 (5) ◽  
pp. 2309-2316 ◽  
Author(s):  
Yogeshwar Makanji ◽  
Craig A. Harrison ◽  
Peter G. Stanton ◽  
Radha Krishna ◽  
David M. Robertson

Inhibin A and B, important regulators of normal function in tissues of the reproductive axis, are glycosylated at either Asn268 or Asn268 and Asn302 in the α-subunit to produce 31- and 34-kDa isoforms, respectively. In this study, glycosylated isoforms of recombinant human inhibin A and B were purified from conditioned medium using immunoaffinity chromatography and reversed-phase HPLC. The masses of the purified inhibin preparations were determined by several inhibin immunoassays, and their in vitro bioactivities were based on suppression of FSH release by rat pituitary cells in culture. Based on a ratio of in vitro bioactivity to immunoactivity (B:I ratio), the monoglycosylated 31-kDa inhibin A was 5-fold more potent than the diglycosylated 34-kDa inhibin A (B:I ratio, 1.22 ± 0.15 vs. 0.24 ± 0.05; P &lt; 0.001, respectively). The 31-kDa inhibin B was significantly (P &lt; 0.001) more potent (1.75 ± 0.29) than the 34-kDa form (1.08 ± 0.20). Because inhibin biological activity is dependent upon interactions with the coreceptor betaglycan, the effect of inhibin glycosylation on betaglycan binding was assessed. Analogous to the pattern of in vitro bioactivity, 31-kDa inhibin A was 12-fold more active (IC50, 0.68 nm) than the 34-kDa isoform (IC50, 8.2 nm) at displacing [125I]inhibin A from COS7 cells expressing betaglycan. However, the 1.6-fold difference in bioactivity of the inhibin B isoforms was not matched by differences in their affinities for betaglycan. It is concluded that glycosylation of Asn302 of the α-subunit of inhibin A and B results in a decrease in bioactivity, and the effect on inhibin A, at least, is explained by its reduced affinity to betaglycan.


2004 ◽  
Vol 183 (1) ◽  
pp. 217-233 ◽  
Author(s):  
Catherine Roche ◽  
Alfredo J Zamora ◽  
David Taïeb ◽  
Esteban Lavaque ◽  
Ramahefarizo Rasolonjanahary ◽  
...  

Despite important advances in human therapeutics, no specific treatment for both non-functioning gonadotroph and resistant somatotroph adenomas is available. Gene transfer by viral vectors can be considered as a promising way to achieve a specific and efficient treatment. Here we show the possibility of efficient gene transfer in human pituitary adenoma cells in vitro using a human immunodeficiency virus (HIV)-type 1-derived vector. Using enhanced green fluorescent protein (eGFP) gene as a marker placed under the phosphoglycerate kinase (PGK) promoter, gonadotroph and somatotroph adenomas were transduced even with moderate viral loads. The expression started at day 2, reached a peak at day 5, and it was still present at day 90. For targeting somatotroph and gonadotroph adenomas, human growth hormone (GH) promoter (GH −481, +54 bp) and two fragments of the human glycoprotein hormone α-subunit promoter (α-subunit 1 −520, +33 bp, and α-subunit 2 −907, +33 bp) were tested. In gonadotroph adenomas, the percentage of identified fluorescent cells and the fluorescence intensity analyzed by fluorescence-activated cell sorting indicated that the strength of the α-subunit 1 and α-subunit 2 promoters were comparable to that of the PGK promoter. Primary cultures of rat pituitary cells showed that α-subunit 1 is more selective to thyreotroph and gonadotroph phenotypes than α-subunit 2. GH promoter activity appeared weak in somatotroph adenomas. The human GH enhancer did not increase the GH promoter activity at all but the human prolactin promoter (−250 bp) allowed 4-fold more fluorescent cells to be obtained than the GH promoter. Several cell lines appeared too permissive to test cell-specificity of pituitary promoters. However, on human non-pituitary cell cultures, the tested pituitary promoters seemed clearly selective to target endocrine pituitary phenotypes. This study gives a starting point for a gene-therapy program using lentiviral vectors to transfer therapeutic genes in human pituitary adenomas.


Sign in / Sign up

Export Citation Format

Share Document